We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance.
- Authors
Aghel, Nazanin; Delgado, Diego Hernan; Lipton, Jeffrey Howard
- Abstract
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment and outcomes of chronic myeloid leukemia (CML). Despite their significant impact on the management of CML, there is growing evidence that TKIs may cause cardiovascular and/or metabolic complications. In this review, we present the current evidence regarding the cardiovascular safety profiles of BCR-ABL TKIs. Methodological challenges of studies that reported the cardiovascular safety of TKIs are discussed. We also propose management strategies for cardiovascular surveillance and risk factor modification during treatment with these agents.
- Subjects
CARDIOTOXICITY; PROTEIN-tyrosine kinase inhibitors; ARTERIAL diseases; TREATMENT of chronic myeloid leukemia; CARDIOVASCULAR disease prevention; CARDIOVASCULAR disease diagnosis; PROTEIN metabolism; ANIMALS; ANTINEOPLASTIC agents; CARDIOVASCULAR diseases; DRUG therapy; DECISION making; PROTEINS; RISK assessment; MYELOID leukemia; PREDICTIVE tests; PATIENT selection; PROTEIN kinase inhibitors; CHEMICAL inhibitors
- Publication
Vascular Health & Risk Management, 2017, Vol 13, p293
- ISSN
1176-6344
- Publication type
journal article
- DOI
10.2147/VHRM.S108874